A Blinded Placebo-controlled Randomized Trial On The Use Of Astaxanthin As An Adjunct To Splinting In The Treatment Of Carpal Tunnel Syndrome
Notes for this study:
||CTS Symptom Severity Scale. Mean and SD. Placebo: before 31 (8), after 28 (9). Astaxanthin: before 35 (9), after 31 (10). CTS Functional Scale/40. Placebo: before 18 (8), after 17 (7). Astaxanthin: before 20 (7), after 19 (8).
|Number of Subjects
||18-29, 30-44, 45-64
In a randomized, triple-blind, placebo-controlled trial, 63 participants with carpal tunnel syndrome were allocated to take 4 mg of astaxanthin daily in addition to splinting, or placebo in addition to splinting for 12 weeks.
Funding issues for this study:
The primary outcome was the severity of symptoms as measured by the Symptom Severity Scale for CTS, and there wasn't a statistically significant difference for the change in symptom severity of function between groups. There also wasn't a difference for DASH, SD-36, and impairment measures or electrodiagnostic studies. There was no notable change in lipid profile as well.
No notable difference in side-effects was found, and no moderate or severe adverse events took place.
"We would like to acknowledge support of Anthony Almada for contributing to study design/oversight of astaxanthin formulation and of IMAGINutrition/Meta Response Sciences for funding of the study."